The importance of TNF-α in intestinal inflammation of CD has been well validated by clinical and animal studies demonstrating the efficacy of anti-TNF-α antibody therapy in the treatment of moderate-to-severe active CD [23–26] and in animal models of intestinal inflammation [27–30]. The gene discussed is TNF; the disease is Cowden disease.